Navigation Links
Verizon Wireless' Network Supports VectraCor's Ambulatory Cardiac Monitor
Date:1/10/2012

LAS VEGAS, BASKING RIDGE, N.J., and TOTOWA, N.J., Jan. 10, 2012 /PRNewswire/ -- From the 2012 International Consumer Electronics Show (CES), Verizon Wireless and VectraCor, Inc. today said the Vectraplex Holter System is being shown at the Verizon booth (Las Vegas Convention Center, South Hall, Booth #30259). 

The Vectraplex Holter System is an ambulatory cardiac monitor that incorporates an electrocardiogram (ECG) amplifier and a cell module using Verizon Wireless service.  Currently under development, the Vectraplex Holter will use the "Cardiac Electrical Biomarker," VectraplexAMI, which received FDA approval in November 2011, on VectraCor's VectraplexECG System.  This technology will detect ECG changes indicative of an acute myocardial infarction (AMI, heart attack), non-invasively and in real time, and display a derived 15 lead ECG from the acquisition of 3 leads (5 electrodes).  For the first time, a patient can be anywhere on the Verizon Wireless network and the Vectraplex Holter System will automatically send an email over the network to the physician when the patient is having ECG changes indicative of an AMI or other events, allowing the physician to review the derived 15 lead ECG.  The device will also send data on patient-initiated events.

Cardiovascular disease is the No. 1 killer in the world, and the need to improve the detection and monitoring of a heart attack is crucial.  The current emergency room practice of chest pain evaluation is to connect the patient to a cardiac monitor (3-5 electrodes), then connect an additional 12 lead ECG machine (additional 10 electrodes), and then draw blood to measure serum biomarkers, repeated approximately every three to six hours during an 18- to 24-hour-period.

The Vectraplex Holter System is an ambulatory cardiac monitor that patients can wear at home or in the hospital to detect ECG changes suggestive of an AMI within seconds and derive the 15 lead ECG (12 lead and vectorcardiogram XYZ leads, including VCG loops) from the acquisition of only 3 leads (5 electrodes).  VectraCor's disruptive technology is patented worldwide and will provide valuable clinical information to both patients and clinicians.

Brad S. Schreck, president and chief executive officer for VectraCor, said, "VectraCor is very pleased to work with Verizon Wireless, enabling our disruptive technology to help patients with cardiovascular disease, the No. 1 killer in the world.  We expect to submit the 510k to the FDA in the first quarter of 2012 for this new product."

Verizon established its Innovation Program to encourage collaboration and help advance the 4G LTE ecosystem.  The company's LTE Innovation Center in Waltham, Mass., and its Application Innovation Center in San Francisco were created to inspire, enable and develop non-traditional devices, services and applications that take advantage of Verizon Wireless' industry-leading wireless networks.  Through the Innovation Program, Verizon seeks to expand the possibilities of 4G LTE by working with diverse companies, from start-ups to established players, in industries representing a broad range of verticals.

For more information about Verizon at CES, visit www.verizonwireless.com/ces or follow Verizon Wireless news on Twitter at @VZWnews.  Visit www.vectracor.com for more information about VectraCor.

About Verizon Wireless
Verizon Wireless operates the nation's largest 4G LTE network and largest, most reliable 3G network. The company serves 107.7 million total wireless connections, including 90.7 million retail customers.  Headquartered in Basking Ridge, N.J., with nearly 83,000 employees nationwide, Verizon Wireless is a joint venture of Verizon Communications (NYSE, NASDAQ: VZ) and Vodafone (LSE, NASDAQ: VOD).  For more information, visit www.verizonwireless.com. To preview and request broadcast-quality video footage and high-resolution stills of Verizon Wireless operations, log on to the Verizon Wireless Multimedia Library at www.verizonwireless.com/multimedia.    

About VectraCor, Inc.
VectraCor is a medical device company in Totowa, NJ with disruptive patented technology in the cardiovascular market place.  Cardiovascular disease is the #1 disease and killer in the US and World.  VectraCor's technology has the potential to be the new standard of care in cardiac monitoring. For more information please visit VectraCor at www.vectracor.com or contact Brad S. Schreck at 973-768-0402 or email bschreck@vectracor.com.  


'/>"/>
SOURCE Verizon Wireless
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Verizon Wireless and Medco Unveil First Mobile Medication App with Real-Time Patient-Specific Drug Safety and Savings Information
2. BL Healthcares Next Generation of Wireless Remote Healthcare Solutions, Now on Verizon Wireless 4G LTE Mobile Broadband Network
3. Verizon Expands Medical Data Exchange to Include Broader Range of Patient Health Data
4. Specialized Verizon Business Security Consulting Services Help Identify, Protect Personal Health Data
5. Verizon Business Adds Riverbed Application Acceleration Technology, New Consulting Services to Boost Performance of Key Business Applications
6. Verizon Wireless Offers Home Health Care Industry Custom Mobile Application To Be More Productive
7. Wireless Engineering Pioneer Joins NYU-Poly and NYU
8. Sotera Wireless Completes $12.2 Million Series D Financing, Signs Agreement with Cerner
9. Hello Health Inc. to Wirelessly Integrate the Hello Health® Patient Management Platform onto Qualcomm Lifes 2net Platform
10. BodyMedia Plans to Join Qualcomm Lifes Wireless Health 2net Ecosystem
11. CareFusion Launches Wireless Diagnostic and Monitoring Neurological Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Feb. 12, 2016   National Community Pharmacists Association ... MBA issued the following statement today in response to ... the Centers for Medicare & Medicaid Services (CMS) ... beneficiary advocates and others: patient advocacy organizations ... still reviewing the full CMS analysis. Our initial reaction ...
(Date:2/12/2016)... ALEXANDRIA, Va. , Feb. 12, 2016  This ... & Specialty Pharmacy (JMCP) takes an in-depth look ... the recent spike in prescription drug spending, which has ... JMCP Editor-in-Chief Laura E. Happe ... Laura E. Happe , PharmD, MPH. --> ...
(Date:2/12/2016)... , Feb. 12, 2016 Hypermarcas S.A. ... cash tender offer (the "Tender Offer") to purchase ... aggregate principal amount of its 6.500% Senior Notes ... Nos. US44915JAA88/ USP5246AAF05) (the "Notes"). In connection with ... "Consent Solicitation") consents (the "Consents") of the holders ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... ... a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced skills needed ... top students from U.S. universities who will draw from Siemens’ deep knowledge ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... members of South Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on ...
(Date:2/12/2016)... Church, VA (PRWEB) , ... February 12, 2016 , ... CDRH Enforcement Trends: , Back ... http://www.fdanews.com/cdrhenforcementtrends , As Winston Churchill said, “Those who don’t learn from ... will show what to expect when they come knocking this year. But that takes time. ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination , ... of pharmaceutical products, garnering increased attention from all stakeholders in the development of ...
(Date:2/12/2016)... ... 12, 2016 , ... Each year, the American Physical Therapy Association (APTA) offers ... the Anaheim Convention Center. Almost 10,000 physical therapists across the country are expected to ... more about their chosen field and network with their colleagues. As in years ...
Breaking Medicine News(10 mins):